Statin treatment before percutaneous cononary intervention

Area of Science:

• Cardiology
• Nephrology
• Pharmacology

Background:

• 3-hydroxy-3-methyl glutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) are recommended for secondary prevention in patients with coronary artery disease (CAD).
• Statin pre-treatment may improve outcomes for patients undergoing percutaneous coronary intervention (PCI).
• Current guidelines recommend high-dose statins before PCI to reduce periprocedural myocardial infarction risk.

Purpose of the Study:

• To explore the potential cardiac and renal protective effects of statins in patients undergoing coronary angioplasty.
• To investigate the pleiotropic, non-lipid-lowering effects of statins contributing to cardio- and nephroprotection.

Main Methods:

• Review of existing literature and clinical guidelines on statin use in CAD and PCI.
• Analysis of proposed mechanisms for statin-mediated cardio- and nephroprotection.

Main Results:

• Statins improve short- and long-term prognosis in high-risk CAD patients and acute coronary syndrome.
• Statin pre-treatment is linked to better outcomes in PCI patients.
• Potential benefits extend beyond cardiac protection to include renal protection against contrast-induced acute kidney injury.

Conclusions:

• Statins offer significant benefits for secondary prevention in CAD.
• Pleiotropic effects of statins, such as improved endothelial function and reduced inflammation, contribute to both cardiac and renal protection.
• Statin use before PCI may mitigate both myocardial and renal injury, warranting further investigation.